These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11166878)

  • 21. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 22. Africa's vaccines revolution must have research at its core.
    Nature; 2021 Apr; 592(7855):487-488. PubMed ID: 33883739
    [No Abstract]   [Full Text] [Related]  

  • 23. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intellectual property rights and traditional medicine: policy dilemmas at the interface.
    Timmermans K
    Soc Sci Med; 2003 Aug; 57(4):745-56. PubMed ID: 12821021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health innovation networks to help developing countries address neglected diseases.
    Morel CM; Acharya T; Broun D; Dangi A; Elias C; Ganguly NK; Gardner CA; Gupta RK; Haycock J; Heher AD; Hotez PJ; Kettler HE; Keusch GT; Krattiger AF; Kreutz FT; Lall S; Lee K; Mahoney R; Martinez-Palomo A; Mashelkar RA; Matlin SA; Mzimba M; Oehler J; Ridley RG; Senanayake P; Singer P; Yun M
    Science; 2005 Jul; 309(5733):401-4. PubMed ID: 16020723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Technology transfer between academic laboratories and industrial laboratories: licensing].
    Salauze D
    Ann Pharm Fr; 2010 Sep; 68(5):301-5. PubMed ID: 20850001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balancing pills and patents: intellectual property and the HIV/AIDS crisis.
    Nderitu T
    E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022
    [No Abstract]   [Full Text] [Related]  

  • 29. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 30. Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.
    Guennif S
    Appl Health Econ Health Policy; 2017 Oct; 15(5):557-565. PubMed ID: 28120166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The position of intellectual property rights in drug discovery and development from natural products.
    Boyd MR
    J Ethnopharmacol; 1996 Apr; 51(1-3):17-25; discussion 25-7. PubMed ID: 9213613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Technology licensing: lessons from the US experience.
    Sobolski GK; Barton JH; Emanuel EJ
    JAMA; 2005 Dec; 294(24):3137-40. PubMed ID: 16380596
    [No Abstract]   [Full Text] [Related]  

  • 33. Accelerating vaccine development and deployment: report of a Royal Society satellite meeting.
    Bregu M; Draper SJ; Hill AV; Greenwood BM
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2841-9. PubMed ID: 21893549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 35. Patent laws. Report urges leeway for developing world.
    Couzin J; Bagla P
    Science; 2002 Sep; 297(5588):1791. PubMed ID: 12228696
    [No Abstract]   [Full Text] [Related]  

  • 36. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health priorities gain patent reprieve for developing countries.
    Cherry M
    Nature; 2001 Nov; 414(6862):385. PubMed ID: 11719767
    [No Abstract]   [Full Text] [Related]  

  • 38. Medicinal plant genetic resources and international cooperation: the Brazilian perspective.
    Elisabetsky E; Costa-Campos L
    J Ethnopharmacol; 1996 Apr; 51(1-3):111-9; discussion 119-20. PubMed ID: 9213607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
    Resnik DB; DeVille KA
    Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
    [No Abstract]   [Full Text] [Related]  

  • 40. Intellectual property. Plants and intellectual property: an international appraisal.
    Koo B; Nottenburg C; Pardey PG
    Science; 2004 Nov; 306(5700):1295-7. PubMed ID: 15550646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.